This inventor holds 5 USPTO granted patents and 4 published patent applications. Top assignees: I2o Therapeutics, Inc., I20 Therapeutics, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: **The Innovative Contributions of Kelly Ibsen in Diabetes Treatment**
Introduction
Kelly Ibsen, an accomplished inventor based in Boston, MA, has made significant strides in the field of pharmaceuticals with her innovative work. She is the holder of three patents that focus on the treatment of metabolic diseases and disorders, showcasing her dedication to improving health outcomes for individuals suffering from conditions such as diabetes and obesity.
Latest Patents
Ibsen's latest patents include groundbreaking compositions that comprise pharmaceutically acceptable salts of glucagon-like peptide-1 (GLP-1) analogs. These compounds are outlined with specific structural formulations, exhibiting an anion:cation molar ratio ranging from about 1:1 to about 1:7. Her work highlights methods for utilizing these compounds in treating metabolic diseases, including type 1 and type 2 diabetes, aiding in weight reduction for subjects in need. This advancement in pharmacological applications marks a significant contribution to the medical and scientific communities focused on addressing urgent health issues.
Career Highlights
Throughout her career, Kelly Ibsen has been associated with notable companies such as I20 Therapeutics, Inc. and I2o Therapeutics, Inc. Her work in these organizations has been pivotal in advancing innovative solutions in pharmaceutical sciences. She has garnered respect in the industry not only for her patents but also for her relentless pursuit of scientific excellence.
Collaborations
In her endeavors, Ibsen has collaborated with a talented team, including her coworker Tyler Brown, who has been instrumental in supporting her research initiatives. Their combined expertise has contributed to developing new therapies that stand to benefit many patients struggling with metabolic disorders.
Conclusion
In conclusion, Kelly Ibsen's contributions to the field of pharmaceuticals are noteworthy. Her innovative patents and collaborations are paving the way for advancements in the treatment of diabetes and obesity. As she continues to work towards improving therapeutic options, her influence in the medical landscape remains significant.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile